Dudediligence.

Oramed Pharmaceuticals Inc

ORMPNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$2.0MMar ’25$0.00Dec ’25
Net income, by quarter
−$19.6MSep ’24−$10.2MDec ’24−$7.6MMar ’25$13.3MJun ’25$48.4MSep ’25−$54.0MDec ’25$38.3MMar ’26$78.2MJun ’26
Fiscal years, by the month each ended
LineAug 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$2.7M$2.7M$1.3Mnone on file$2.0M
Gross profitnone on filenone on filenone on filenone on file$13,000
Operating income−$24.2M−$40.6M−$15.8M−$12.8M−$15.1M
Net income−$23.0M−$36.6M$5.1M−$19.1M$75,324
Operating cash flow−$21.2M−$27.9M−$10.3M−$8.4M−$9.1M
Free cash flow−$21.6M−$28.4M−$10.5M−$8.4M−$9.2M
Cash$77.2M$40.5M$9.1M$54.4M$45.9M
Debtnone on file$25,000$51.0Mnone on filenone on file
Shares outstanding35.3M39.6M40.3M39.9M39.3M